公共卫生领域疾病诊断中生物标志物识别、验证与开发的相关问题。 - Suppr

Suppr

超能文献

Issues in biomarker identification, validation and development for disease diagnostics in Public Health.

作者信息

Kempsell Karen E, Ball Graham, Szakmany Tamas

机构信息

a Diagnostic Technologies Group, Infection Services , Health Protection Agency Porton , Salisbury , Wiltshire , UK.

b School of Science and Technology , Nottingham Trent University , Nottingham , UK.

出版信息

Expert Rev Mol Diagn. 2016;16(4):383-6. doi: 10.1586/14737159.2016.1133300. Epub 2016 Jan 22.

DOI:10.1586/14737159.2016.1133300

PMID:26680111

Abstract

摘要

相似文献

Issues in biomarker identification, validation and development for disease diagnostics in Public Health.

Expert Rev Mol Diagn. 2016;16(4):383-6. doi: 10.1586/14737159.2016.1133300. Epub 2016 Jan 22.

Multiplexed testing for HIV and related bacterial and viral co-infections at the point-of-care: quo vadis?

Expert Rev Mol Diagn. 2015 Apr;15(4):463-9. doi: 10.1586/14737159.2015.1021335.

Sample-to-result molecular infectious disease assays: clinical implications, limitations and potential.

Expert Rev Mol Diagn. 2016;16(3):323-41. doi: 10.1586/14737159.2016.1134325. Epub 2016 Jan 11.

Establishing the Evidence Bar for Molecular Diagnostics in Personalised Cancer Care.

Public Health Genomics. 2015;18(6):349-58. doi: 10.1159/000441556. Epub 2015 Nov 11.

Drug-diagnostic co-development: challenges and issues.

Expert Rev Mol Diagn. 2016;16(2):187-204. doi: 10.1586/14737159.2016.1132163. Epub 2016 Jan 13.

Precision medicine: what's all the fuss about?

Scand J Clin Lab Invest Suppl. 2016;245:S2-5. doi: 10.1080/00365513.2016.1206434. Epub 2016 Aug 17.

The promise of biomarkers in cancer screening and detection.

Trends Mol Med. 2002 Jun;8(6):288-93. doi: 10.1016/s1471-4914(02)02353-5.

The national biomarker development alliance: confronting the poor productivity of biomarker research and development.

Expert Rev Mol Diagn. 2015 Feb;15(2):211-8. doi: 10.1586/14737159.2015.974561. Epub 2014 Nov 25.

Transcriptional biomarkers--high throughput screening, quantitative verification, and bioinformatical validation methods.

Methods. 2013 Jan;59(1):3-9. doi: 10.1016/j.ymeth.2012.08.012. Epub 2012 Sep 4.

Clinical Performance Evaluation of Molecular Diagnostic Tests.

J Mol Diagn. 2016 Nov;18(6):803-812. doi: 10.1016/j.jmoldx.2016.06.008. Epub 2016 Sep 15.

引用本文的文献

Plasma IgM Levels Differentiate between Survivors and Non-Survivors of Culture-Positive and Culture-Negative Sepsis and SIRS: A Pilot Study.

J Clin Med. 2021 Nov 19;10(22):5391. doi: 10.3390/jcm10225391.

Lactoferrin Concentration in Human Tears and Ocular Diseases: A Meta-Analysis.

Invest Ophthalmol Vis Sci. 2020 Oct 1;61(12):9. doi: 10.1167/iovs.61.12.9.

Identification and validation of host biomarkers for leprosy: A step forward to establish point-of-care tests.

EBioMedicine. 2019 Oct;48:9-10. doi: 10.1016/j.ebiom.2019.09.028. Epub 2019 Oct 17.

Soluble Toll-like receptor 2 is a biomarker for sepsis in critically ill patients with multi-organ failure within 12 h of ICU admission.

Intensive Care Med Exp. 2017 Dec;5(1):2. doi: 10.1186/s40635-016-0116-z. Epub 2017 Jan 13.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Issues in biomarker identification, validation and development for disease diagnostics in Public Health.

作者信息

Kempsell Karen E, Ball Graham, Szakmany Tamas

机构信息

a Diagnostic Technologies Group, Infection Services , Health Protection Agency Porton , Salisbury , Wiltshire , UK.

b School of Science and Technology , Nottingham Trent University , Nottingham , UK.

出版信息

Expert Rev Mol Diagn. 2016;16(4):383-6. doi: 10.1586/14737159.2016.1133300. Epub 2016 Jan 22.

DOI:10.1586/14737159.2016.1133300

PMID:26680111

Abstract

摘要

相似文献

Issues in biomarker identification, validation and development for disease diagnostics in Public Health.

Expert Rev Mol Diagn. 2016;16(4):383-6. doi: 10.1586/14737159.2016.1133300. Epub 2016 Jan 22.

Multiplexed testing for HIV and related bacterial and viral co-infections at the point-of-care: quo vadis?

Expert Rev Mol Diagn. 2015 Apr;15(4):463-9. doi: 10.1586/14737159.2015.1021335.

Sample-to-result molecular infectious disease assays: clinical implications, limitations and potential.

Expert Rev Mol Diagn. 2016;16(3):323-41. doi: 10.1586/14737159.2016.1134325. Epub 2016 Jan 11.

Establishing the Evidence Bar for Molecular Diagnostics in Personalised Cancer Care.

Public Health Genomics. 2015;18(6):349-58. doi: 10.1159/000441556. Epub 2015 Nov 11.

Drug-diagnostic co-development: challenges and issues.

Expert Rev Mol Diagn. 2016;16(2):187-204. doi: 10.1586/14737159.2016.1132163. Epub 2016 Jan 13.

Precision medicine: what's all the fuss about?

Scand J Clin Lab Invest Suppl. 2016;245:S2-5. doi: 10.1080/00365513.2016.1206434. Epub 2016 Aug 17.

The promise of biomarkers in cancer screening and detection.

Trends Mol Med. 2002 Jun;8(6):288-93. doi: 10.1016/s1471-4914(02)02353-5.

The national biomarker development alliance: confronting the poor productivity of biomarker research and development.

Expert Rev Mol Diagn. 2015 Feb;15(2):211-8. doi: 10.1586/14737159.2015.974561. Epub 2014 Nov 25.

Transcriptional biomarkers--high throughput screening, quantitative verification, and bioinformatical validation methods.

Methods. 2013 Jan;59(1):3-9. doi: 10.1016/j.ymeth.2012.08.012. Epub 2012 Sep 4.

Clinical Performance Evaluation of Molecular Diagnostic Tests.

J Mol Diagn. 2016 Nov;18(6):803-812. doi: 10.1016/j.jmoldx.2016.06.008. Epub 2016 Sep 15.

引用本文的文献

Plasma IgM Levels Differentiate between Survivors and Non-Survivors of Culture-Positive and Culture-Negative Sepsis and SIRS: A Pilot Study.

J Clin Med. 2021 Nov 19;10(22):5391. doi: 10.3390/jcm10225391.

Lactoferrin Concentration in Human Tears and Ocular Diseases: A Meta-Analysis.

Invest Ophthalmol Vis Sci. 2020 Oct 1;61(12):9. doi: 10.1167/iovs.61.12.9.

Identification and validation of host biomarkers for leprosy: A step forward to establish point-of-care tests.

EBioMedicine. 2019 Oct;48:9-10. doi: 10.1016/j.ebiom.2019.09.028. Epub 2019 Oct 17.

Soluble Toll-like receptor 2 is a biomarker for sepsis in critically ill patients with multi-organ failure within 12 h of ICU admission.

Intensive Care Med Exp. 2017 Dec;5(1):2. doi: 10.1186/s40635-016-0116-z. Epub 2017 Jan 13.